121 related articles for article (PubMed ID: 21704168)
21. Reciprocal immunohistochemical expression of sodium/iodide symporter and hexokinase I in primary thyroid tumors with synchronous cervical metastasis.
Jung YH; Hah JH; Sung MW; Kim KH; Cho SY; Jeon YK
Laryngoscope; 2009 Mar; 119(3):541-8. PubMed ID: 19235753
[TBL] [Abstract][Full Text] [Related]
22. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line.
Jeong H; Kim YR; Kim KN; Choe JG; Chung JK; Kim MK
Nucl Med Biol; 2006 Oct; 33(7):875-82. PubMed ID: 17045167
[TBL] [Abstract][Full Text] [Related]
23. Radioiodine ablation: when and how.
Ambrosetti MC; Colato C; Dardano A; Monzani F; Ferdeghini M
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):473-81. PubMed ID: 19910900
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
[TBL] [Abstract][Full Text] [Related]
25. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
26. Thyroid cancer in young adults.
Ying AK; Huh W; Bottomley S; Evans DB; Waguespack SG
Semin Oncol; 2009 Jun; 36(3):258-74. PubMed ID: 19460583
[TBL] [Abstract][Full Text] [Related]
27. Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective.
Higashi T; Kudo T; Kinuya S
Ann Nucl Med; 2012 Feb; 26(2):99-112. PubMed ID: 22081274
[TBL] [Abstract][Full Text] [Related]
28. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
Kojic KL; Kojic SL; Wiseman SM
Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
30. Regulation of the sodium/iodide symporter by retinoids--a review.
Schmutzler C
Exp Clin Endocrinol Diabetes; 2001; 109(1):41-4. PubMed ID: 11573138
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib in the Treatment of Thyroid Cancer.
Ferrari SM; Centanni M; Virili C; Miccoli M; Ferrari P; Ruffilli I; Ragusa F; Antonelli A; Fallahi P
Curr Med Chem; 2019; 26(6):963-972. PubMed ID: 28990511
[TBL] [Abstract][Full Text] [Related]
32. Novel targeted therapies and immunotherapy for advanced thyroid cancers.
Naoum GE; Morkos M; Kim B; Arafat W
Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653
[TBL] [Abstract][Full Text] [Related]
33. Thyroid Gland Malignancies.
Cabanillas ME; Dadu R; Hu MI; Lu C; Gunn GB; Grubbs EG; Lai SY; Williams MD
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1123-43. PubMed ID: 26568552
[TBL] [Abstract][Full Text] [Related]
34. Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system.
Oh JM; Kalimuthu S; Gangadaran P; Baek SH; Zhu L; Lee HW; Rajendran RL; Hong CM; Jeong SY; Lee SW; Lee J; Ahn BC
Oncotarget; 2018 Jan; 9(6):7075-7087. PubMed ID: 29467951
[TBL] [Abstract][Full Text] [Related]
35. Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer.
Riesco-Eizaguirre G; Galofré JC; Grande E; Zafón Llopis C; Ramón y Cajal Asensio T; Navarro González E; Jiménez-Fonseca P; Santamaría Sandi J; Gómez Sáez JM; Capdevila J
Endocrinol Nutr; 2016 Apr; 63(4):e17-24. PubMed ID: 26601805
[TBL] [Abstract][Full Text] [Related]
36. Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer.
Ibrahim EY; Busaidy NL
Curr Opin Oncol; 2017 Mar; 29(2):151-158. PubMed ID: 28141684
[TBL] [Abstract][Full Text] [Related]
37. Thyroid cancer: emerging role for targeted therapies.
Sipos JA; Shah MH
Ther Adv Med Oncol; 2010 Jan; 2(1):3-16. PubMed ID: 21789122
[TBL] [Abstract][Full Text] [Related]
38. Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects.
Puliafito I; Esposito F; Prestifilippo A; Marchisotta S; Sciacca D; Vitale MP; Giuffrida D
Front Endocrinol (Lausanne); 2022; 13():860671. PubMed ID: 35872981
[TBL] [Abstract][Full Text] [Related]
39. Theranostics in Thyroid Cancer.
Eilsberger F; Pfestroff A
PET Clin; 2021 Jul; 16(3):375-382. PubMed ID: 34053581
[TBL] [Abstract][Full Text] [Related]
40. Role of albumin Cys34 redox state in the progression of differentiated thyroid carcinoma and induction of ferroptosis.
Inoue M; Iizuka Y; Nakamura K; Sato GE; Mizowaki T
Free Radic Biol Med; 2023 Nov; 209(Pt 1):108-115. PubMed ID: 37806598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
